Aquestive Therapeutics Inc (NASDAQ:AQST) price target lowered to $21.00 by BMO Capital Markets

Aquestive Therapeutics Inc (NASDAQ:AQST) price target lowered to $21.00 by BMO Capital Markets

Mar 15, 2019 (Market Exclusive via COMTEX) —

Analyst Ratings For Aquestive Therapeutics Inc (NASDAQ:AQST)

Today, BMO Capital Markets lowered its price target on Aquestive Therapeutics Inc (NASDAQ:AQST) to $21.00 per share.

There are 5 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Aquestive Therapeutics Inc (NASDAQ:AQST) is Buy with a consensus target price of $23.60 per share, a potential 265.89% upside.

Some recent analyst ratings include

2/20/2019-Aquestive Therapeutics Inc (NASDAQ:AQST) had its Buy rating reiterated by Lake Street Capital 8/20/2018-Aquestive Therapeutics Inc (NASDAQ:AQST) has coverage initiated with a Outperform rating and $29.00 price target

About Aquestive Therapeutics Inc (NASDAQ:AQST)
Aquestive Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. Its products are developed using its PharmFilm technology. The company’s marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery. Its proprietary product candidates that are in development comprise AQST-203, a buccally, an administered soluble film formulation of diazepam for the treatment of recurrent epileptic seizures; AQST-120, an oral soluble film formulation of clobazam for the treatment of seizures associated with a rare, intractable form of epilepsy; and AQST-117, an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The company’s development products also include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; AQST-305, a buccal film formulation of octreotide for the treatment of acromegaly and neuroendocrine tumors; APL-130277, a sublingual film formulation of apomorphine

Read More Here...

Bookmark the permalink.